Back to results
US 2008/0305171 A1Published application
Pyrrolopyrazine, formulations, methods of manufacture, and methods of use there
OwnerKristin Anne Arnold, Jie Du +3inventors
InventorsKristin Anne Arnold, Jie Du, Kurt Nielsen, Hongmei M. Sheridan, Shawn M. Watson
Life of this patent
Estimating the term…
Abstract
Disclosed herein is a pyrrolopyrazine COMPOUND I having defined amounts of R isomer, particle size, and stability. Also disclosed are pyrrolopyrazine oral dosage forms comprising the described COMPOUND I material as well as methods of treating disorders amenable to therapy using COMPOUND I.
Claims33
COMPOUND I,
- or a pharmaceutically acceptable salt thereof, comprising 0.3 to about 1% of the R isomer based on the total amount of S and R isomers or pharmaceutically acceptable salt thereof.
(canceled)
-5. (canceled)
-10. (canceled)
(canceled)
An oral dosage form, comprising:
- a therapeutically effective amount of COMPOUND I, or a pharmaceutically acceptable salt thereof, comprising 0.3 to about 1% of the R isomer based on the total amount of S and R isomers or pharmaceutically acceptable salt thereof;
- and
- a pharmaceutically acceptable excipient.
(canceled)
-18. (canceled)
-23. (canceled)
-35. (canceled)
An oral dosage form, comprising:
- a therapeutically effective amount of COMPOUND I, or a pharmaceutically acceptable salt thereof, comprising 0.3 to about 1% of the R isomer based on the total amount of S and R isomers or pharmaceutically acceptable salt thereof;
- and
- a pharmaceutically acceptable excipient;
- wherein the amount of R isomer present in the COMPOUND I remains substantially unchanged between an initial time point and after storage of the COMPOUND I at about 25° C. and about 60% relative humidity for 12 months, and
- wherein the COMPOUND I has an average particle size about 0.1 to about 500 micrometers.
2 more elements
(canceled)
(canceled)
-47. (canceled)
-51. (canceled)
-58. (canceled)
Dependencies are inferred from the claim text.